T au aggregation characterizes a series of neurodegenerative diseases including AD and other tauopathies. The distribution of Tau deposits correlates with the loss of neurons in these neurodegenerative diseases, and Tauinduced toxicity depends on its ability to aggregate. We have used an inducible cell model to study the expression of Tau variants, the buildup of aggregates, and their removal by the autophagy-lysosomal system. Incomplete chaperone-mediated autophagy of Tau generates amyloidogenic fragments that promote aggregation. The Tau aggregates are removed from cells by macroautophagy. Thus the two autophagic pathways could become possible therapeutic targets.
Protein aggregation is a common feature of many neurodegenerative disorders. In the case of Alzheimer disease (AD) and other "tauopathies" (e.g., Parkinson, frontotemporal dementia) one observes the aggregation of the cytosolic protein "Tau" which normally serves to stabilize microtubules, the tracks for axonal transport. Cells possess two major routes of degrading pathogenic proteins. The autophagy-lysosomal system has the capacity to engulf protein aggregates, while the proteasomal system lacks such ability, as the narrow barrel of the proteasome allows cleavage of single proteins but precludes entry of aggregates. It is therefore pertinent to ask if and what role the autophagy-lysosomal system plays in the degradation of soluble and aggregated forms of proteins such as Tau. To this end, we made use of our This manuscript has been published online, prior to printing. Once the issue is complete and page numbers have been assigned, the citation will change accordingly. recently developed cell model of tauopathy. In this model, the repeat domain of Tau harboring one of the mutations of Tau (∆K280) observed in frontotemporal dementia (Tau RD ∆K280) is expressed in a regulatable fashion (tet-on). The protein undergoes successive cleavages by several proteases, first in the N terminus (F1) and subsequently in its C terminus leading to the generation of fragments (F2 and F3) that have a high propensity for beta structure and for aggregation. The aggregates contain not only the nucleating fragments, but also the parent protein and even endogenous full-length Tau protein (Fig. 1) .
Both soluble and aggregated Tau can be degraded by macroautophagy in this cell model, as macroautophagy inhibitors (3-methyladenine and bafilomycin A 1 ) dramatically increase soluble and sarkosylinsoluble levels of Tau RD ∆K, which are detected in autophagosomes and lysosomes when macroautophagy is not inhibited. Inhibition of macroautophagy leads to enhanced aggregation and cytotoxicity, as seen by a strong increase of thioflavin S-stained cells and LDH release. Surprisingly, treatment with NH 4 Cl, which inhibits lysosomal protease activity by neutralizing the acidic lysosomal pH, does not promote Tau aggregation. On the contrary, NH 4 Cl reduces Tau aggregation by preventing the generation of F2 and F3, supporting the view that lysosomes might be the source of proteases for generating these fragments. However, this idea posed a conceptual problem: How can the lysosome contribute to Tau cleavage, yet promote aggregation in the cytosol? Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation In addition, using a cell model overexpressing the wild-type full-length 4-repeat Tau, we show that full-length Tau can also be degraded by the autophagy-lysosomal system, consistent with reports from D. Rubinsztein's lab. Several groups (Kosik K, Petrucelli L, Dickey C) recently report that Tau hyperphosphorylated at the SerPro or Thr-Pro motifs in the flanking domains of the repeats can be ubiquitinated and then targeted for proteasomal degradation by the CHIP/hsc70 complex. However, Tau phosphorylated at the KXGS motifs of the repeats was thought to be protected against this pathway, so that it remained unclear how degradation of this protein takes place. In this case we show that Tau phosphorylated at the KXGS motifs of the repeat domains can be degraded by the autophagy-lysosomal system. Thus, depending on the state of phosphorylation, Tau molecules can be degraded by both proteasomal and autophagy-lysosomal systems.
Recently, R. Nixon's group reports that in AD brain, the autophagy-lysosomal system is disturbed, which may promote the accumulation of β-amyloid. Thus, the fact that the autophagy-lysosomal pathway might play a role in the pathogenesis of both neurofibrillary tangles and senile plaques-the two hallmarks of AD-makes it an attractive target for future therapeutic interventions.
the generation of the pathogenic F2 and F3 fragments on the surface of the lysosomes. This partial translocation of a protein via CMA observed here is reminiscent of the blockage in CMA lysosomal translocation of other pathogenic proteins, e.g., mutant α-synucleins. We further confirmed that the delivery of Tau to lysosomes depends on CMA because knockdown of LAMP-2A in this cell model or mutations in the KFERQ-like motifs of Tau RD ∆K suppresses generation of F2 and F3. These results confirm that incomplete CMA of Tau is involved in the generation of the amyloidogenic F2 and F3 fragments.
Based on these data, we proposed the following model to depict how the autophagy-lysosomal system might generate aggregates in a cell model (Fig. 1) . When Tau RD ∆K is expressed in N2a cells, it is first cleaved by a "thrombinlike" activity in the cytosol to generate fragment F1. This is then delivered to lysosomes via CMA, where its partial translocation allows cathepsin L-mediated cleavage of the C terminus to generate F2 and F3. Part of the truncated products remain initially associated with the lysosomal membrane favoring oligomerization at or near the surface of the organelle and eventually resulting in membrane
In fact, we showed that recombinant F1 could indeed be cleaved to generate F2 and F3 when incubated with lysosomal extracts, and we identified cathepsin L as the protease responsible for these dual cleavages. To search for a pathway distinct from macroautophagy that would deliver Tau constructs to lysosomes, we turned our attention to another form of autophagy, chaperone-mediated autophagy (CMA ). A cytosolic chaperone, hsc70, recognizes this type of motif in CMA substrates and delivers them to the lysosomal LAMP-2A receptor. To determine whether Tau could be translocated into the lysosomal lumen via CMA, we used an in vitro assay with intact isolated lysosomes that allows measurement of substrate binding, uptake and degradation via CMA. Tau RD ∆K and F1 behave in the binding as bona fide CMA substrates. However, unexpectedly, despite their association with the CMA translocation machinery-hsc70 and LAMP-2A-there is no complete translocation of these Tau constructs into the lysosomal lumen. Instead, the membrane-inserted protein undergoes regulated cleavage by cathepsin L, a lumenal resident protein, resulting in 
